Figure 4: Longitudinal analyses of circulating miRNA levels in response to ongoing therapy in NSCLC patients. | Nature Communications

Figure 4: Longitudinal analyses of circulating miRNA levels in response to ongoing therapy in NSCLC patients.

From: Tumour-initiating cell-specific miR-1246 and miR-1290 expression converge to promote non-small cell lung cancer progression

Figure 4

(a) qRT–PCR analysis of serum miR-1246 and miR-1290 levels in NSCLC patients and healthy individuals. Fold change of miR-1246 and miR-1290 levels is presented as box plot. The median value of serum miR-1246 or miR-1290 levels in healthy individuals was normalized to 1. Data are represented as mean±s.e.m. P values were calculated using Student’s t-tests. T, NSCLC patients (n=59); N, healthy individuals (n=65). (b–d) Changes in serum miR-1246 and miR-1290 levels in response to therapy across multiple time points in NSCLC patients. The clinical disease progression status at various times was determined by CT (upper panel). All patients received EGFR TKI *, and in some instances, followed by either chemo or radiotherapy. The circulating miRNA levels are shown in the middle panel. Patients are categorized into four subgroups based on the pattern of clinical response to treatment. Representative response patterns from Group 1 (b) (response followed by progression; Patients 2 and 8), Group 2 (c) (progression; Patient 1), Group 3 (d) (stable disease; Patient 220) and Group 4 (e) (progression followed by response; Patients 218 and 219) are shown. The linear association between serum miRNAs levels and tumour size was analysed using Pearson’s correlation coefficient (R) by SigmaPlot 11. Baseline CT scan was performed at day 0. EGFR TKI*=gefitinib and hydroxychloroquine.

Back to article page